Monday, 25 Mar 2019

You are here

Laparoscopic Gastric Sleeve Compared to Bypass Bariatric Surgery

JAMA reports the results of a 5 year Finnish study comparing the results of laparoscopic sleeve gastrectomy vs Roux-en-Y gastric bypass and shows that gastric bypass yielded greater weight loss at 5 years, the difference was not statistically significant, in patients with morbid obesity. 

The Sleeve vs Bypass (SLEEVEPASS) study included 240 adults with morbid obesity received open-label randomized intervention iwth either sleeve gastrectomy or gastric bypass with a 5-year follow-up period. The primary end point was weight loss evaluated by percentage excess weight loss. The pPrespecified equivalence margins were −9% to +9% excess weight loss.

The patients had a mean baseline BMI of 45.9, and 42.1% had type 2 diabetes, 34.6% dyslipidemia, and 70.8% hypertension.  The results are shown in the table below:

 SleeveBypass
% Wt. Loss49%57%
DM remission37%45%
D/C Statins47%60%
D/C BP meds29%51%
Morbidity rate19%26%

 

 

 

 

 

 

 

 

While gastric bypass results were generally superior to gastric sleeve results, these were not significantly different. 

These results are similar to that seen in the STAMPEDE study showing similar (nonsignificant) but better results for bypass compared to gastric sleeve in the control of type II diabetes. (citation source: https://buff.ly/2rdYC3M

The five-year follow-up of this original study showed that:

  • 88% of gastric bypass and sleeve gastrectomy patients maintained healthy blood glucose levels without needinginsulin.
  • 29% of gastric bypass patients and 23% of sleeve gastrectomy patients achieved normal blood glucose levels
  • Weight loss was significantly greater with gastric bypass and sleeve gastrectomy compared than with medications 

The effects of both surgical procedures to normalize glucose levels did, however, diminish over time, and some late complications were noted with surgery.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

CRA Position Statement on Medical Cannabis Use

Courtesy of the Canadian Rheumatology Association (CRA) website, here are consensus guidelines on medical cannabis use.

Rheumatology patients experience prevalent pain that is only modestly controlled with current treatment strategies.

Senate Drills Drug Makers Over Price

Reuters reported that today, the US Senate Finance Committee met to question the executives from seven US pharmaceutical companies on the rising price drugs in America. 

Canadian Vaccination Guidelines for the Immunosuppressed

A multidisciplinary Canadian task force has developed guidelines for vaccination in patients receiving immunosuppressive therapies, based on the evidence that immunosuppressive use in immune-mediated disease may be  associated with an elevated risk of infections. 

No Difference in Oral or IV Antibiotics for Bone & Joint Infections

Research from the NEJM shows that oral antibiotic therapy was noninferior to intravenous antibiotic therapy when used during the first six weeks for complex orthopedic infections.

There is considerable discussion whether complex bone and joint infections must be managed with prolonged intravenous antibiotics or if oral antibiotic therapy may suffice. 

2019: the Year of Price Hikes

In 2019 there have been numerous reports of higher drug pricing for many drugs.  Yesterday it was reported that the price of insulin drugs have more than doubled from 2012 to 2016.

Reuters reports that in the United States, the pricing on more than 250 prescription drugs have gone up.